Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
11 studies found for:    "Plasma cell leukemia"
Show Display Options
RSS Create an RSS feed from your search for:
"Plasma cell leukemia"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia
Condition: Primary Plasma Cell Leukemia
Intervention: Drug: Lenalidomide, dexamethasone
2 Recruiting Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia
Conditions: Plasma Cell Leukemia;   Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Liposome doxorubicin;   Drug: Dexamethasone
3 Active, not recruiting Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
Conditions: Multiple Myeloma;   Multiple Myeloma in Relapse;   Mantle Cell Lymphoma in Relapse;   Diffuse Large B Cell Lymphoma in Relapse;   Other B Cell Lymphoma in Relapse;   Plasma Cell Leukemia
Intervention: Biological: SNS01-T
4 Completed
Has Results
Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants
Conditions: Multiple Myeloma;   Plasma Cell Leukemia
Interventions: Drug: Bortezomib;   Drug: Melphalan;   Procedure: PBSCT
5 Not yet recruiting Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Conditions: Acute Myeloid Leukemia (AML);   Acute Lymphocytic Leukemia (ALL);   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myelofibrosis;   Myelodysplasia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Diffuse Large B Cell Lymphoma;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Non-Hodgkin Lymphoma;   Multiple Myeloma
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Cyclosporine A;   Drug: Mycophenylate mofetil;   Biological: Umbilical cord blood
6 Active, not recruiting A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Multiple Myeloma;   Plasma Cell Leukemia
Interventions: Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous;   Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous;   Drug: Dexamethasone, steroid; oral
7 Active, not recruiting Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen
Conditions: Multiple Myeloma;   Plasma Cell Leukemia
Interventions: Drug: Fludarabine/Busulfan x 4 days;   Procedure: stem cell transplant
8 Active, not recruiting A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma, Plasma Cell Leukemia
Interventions: Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous;   Drug: Bortezomib, proteasome inhibitor; intravenous or subcutaneous;   Drug: Dexamethasone, steroid; oral;   Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
9 Terminated Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma
Conditions: Multiple Myeloma;   Leukemia, Plasma Cell
Interventions: Drug: Carfilzomib;   Drug: Melphalan;   Drug: Filgrastim
10 Completed Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Dietary Supplement: ascorbic acid;   Drug: arsenic trioxide;   Drug: bortezomib;   Drug: dexamethasone;   Drug: thalidomide;   Drug: Aspirin
11 Recruiting Arry-520 + Carfilzomib for Multiple Myeloma (MM)
Condition: Myeloma
Interventions: Drug: Arry-520;   Drug: Carfilzomib;   Drug: Dexamethasone;   Drug: Filgrastim

Indicates status has not been verified in more than two years